Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lack of Association of Three Common Polymorphisms in Toll-like receptors (TLRs), TLR2+597T>C, +1350C>T and Arg753Gln with Cancer Risk: a Meta-analysis

  • Yang, Xin (The First Clinical College of Nanjing Medical University) ;
  • Wang, Xiao-Xiao (Department of Bio-statistics, Georgia Health Science University) ;
  • Qiu, Man-Tang (Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province) ;
  • Hu, Jing-Wen (The First Clinical College of Nanjing Medical University) ;
  • Yin, Rong (Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province) ;
  • Xu, Lin (Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province) ;
  • Zhang, Qin (Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province)
  • Published : 2013.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Single nucleotide polymorphisms (SNPs) occurring in Toll-like receptors (TLRs) may contribute to cancer risk. Many polymorphisms of TLR2 have been studied for associations, but the findings are conflicting. Methodology/Principal Findings: We performed a meta-analysis of 14 studies to confirm the association between TLR2+597T>C (rs3804099), +1350C>T (rs3804100) and Arg753Gln (rs5743708) polymorphisms and cancer risk. Odds ratio (OR) and 95% confidence intervals (95% CI) were used to assess the strength of associations. There was no significant association between TLR2+597T>C and cancer risk in the codominant models (CC vs. TT: OR = 1.01, 95%CI = 0.86-1.17, $P_{heterogeneity}=0.148$; CT vs. TT: OR = 0.92, 95%CI = 0.69-1.23, $P_{heterogeneity}$ < 0.001), the recessive model (CC vs. CT+TT: OR = 0.86, 95%CI = 0.67-1.10, $P_{heterogeneity}=0.007$), the dominant model (CC+CT vs. TT: OR = 0.93, 95%CI = 0.76-1.15, $P_{heterogeneity}=0.001$) and the allele model (C vs. T: OR =0.93, 95%CI = 0.81-1.08, $P_{heterogeneity}=0.019$). Similarly, no significant associations between TLR2+1350C>T, Arg753Gln polymorphisms and cancer risk were found. However, in the sub-group analysis of ethnicities, the trend of pooled ORs in Asians was opposite to Caucasians. Conclusions: The present meta-analysis suggests that TLR2+597T>C (rs3804099), +1350C>T (rs3804100) and Arg753Gln (rs5743708) polymorphisms are not associated with cancer risk.

Keywords

References

  1. Akira S, Takeda K, Kaisho T (2001). Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol, 2, 675-80. https://doi.org/10.1038/90609
  2. Ashton KA, Proietto A, Otton G, et al (2010). Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. BMC Cancer, 10, 382. https://doi.org/10.1186/1471-2407-10-382
  3. Balistreri CR Caruso C, Carruba G, et al (2010). A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications. Curr Pharm Des, 16, 718-24. https://doi.org/10.2174/138161210790883877
  4. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  5. Chen K, Huang J, Gong W, et al (2007). Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol, 7, 1271-85. https://doi.org/10.1016/j.intimp.2007.05.016
  6. Chuang T, Ulevitch RJ (2001). Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta, 1518, 157-61. https://doi.org/10.1016/S0167-4781(00)00289-X
  7. Du X, Poltorak A, Wei Y, Beutler B (2000). Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw, 11, 362-71.
  8. Egger M, Davey SG, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  9. El-Omar EM, Ng MT, Hold GL (2008). Polymorphisms in Tolllike receptor genes and risk of cancer. Oncogene, 27, 244-52. https://doi.org/10.1038/sj.onc.1210912
  10. Etokebe GE, Knezevic J, Petricevic B, et al (2009). Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer. Genet Test Mol Biomarkers, 13, 729-34. https://doi.org/10.1089/gtmb.2009.0045
  11. Gast A, Bermejo JL, Claus R, et al (2011). Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival. PLoS One, 6, e24370. https://doi.org/10.1371/journal.pone.0024370
  12. He JF, Jia WH, Fan Q, et al (2007). Genetic polymorphisms of TLR3 are associated with Nasopharyngeal carcinoma risk in Cantonese population. BMC Cancer, 7, 194. https://doi.org/10.1186/1471-2407-7-194
  13. Junjie X, Songyao J, Minmin S, et al (2012). The association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility. BMC Cancer, 12, 57. https://doi.org/10.1186/1471-2407-12-57
  14. Killeen SD, Wang JH, Andrews EJ, Redmond HP (2006). Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword. Br J Cancer, 95, 247-52. https://doi.org/10.1038/sj.bjc.6603275
  15. Kim MK, Park SW, Kim SK, et al (2012). Association of Toll-like receptor 2 polymorphisms with papillary thyroid cancer and clinicopathologic features in a Korean population. J Korean Med Sci, 27, 1333-8. https://doi.org/10.3346/jkms.2012.27.11.1333
  16. Kumar H, Kawai T, Akira S (2009). Toll-like receptors and innate immunity. Biochem Biophys Res Commun, 388, 621-5. https://doi.org/10.1016/j.bbrc.2009.08.062
  17. Kutikhin AG (2011). Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol, 72, 1095-116. https://doi.org/10.1016/j.humimm.2011.07.307
  18. McBride WH, Chiang CS, Olson JL, et al (2004). A sense of danger from radiation. Radiat Res, 162, 1-19. https://doi.org/10.1667/RR3196
  19. Monroy CM, Cortes AC, Lopez MS, et al (2011). Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes. Mol Carcinog, 50, 36-46. https://doi.org/10.1002/mc.20688
  20. Ng MT, Van't HR, Crockett JC, et al (2010). Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9 -1237T/C polymorphism is associated with Helicobacter pylori-induced gastric disease. Infect Immun, 78, 1345-52. https://doi.org/10.1128/IAI.01226-09
  21. Nieters A, Beckmann L, Deeg E, Becker N (2006). Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun, 7, 615-24. https://doi.org/10.1038/sj.gene.6364337
  22. Nischalke HD, Coenen M, Berger C, et al (2012). The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer, 130, 1470-5. https://doi.org/10.1002/ijc.26143
  23. Okamoto M, Sato M (2003). Toll-like receptor signaling in anti-cancer immunity. J Med Invest, 50, 9-24.
  24. Pimentel-Nunes P, Teixeira AL, Pereira C, et al (2013). Functional polymorphisms of Toll-like receptors 2 and 4 alter the risk for colorectal carcinoma in Europeans. Dig Liver Dis, 45, 63-9. https://doi.org/10.1016/j.dld.2012.08.006
  25. Purdue MP, Lan Q, Wang SS, et al (2009). A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis, 30, 275-81.
  26. Qiu MT, Hu JW, Ding XX, et al (2012). Hsa-miR-499 rs3746444 Polymorphism Contributes to Cancer Risk: A Meta-Analysis of 12 Studies. PLoS One, 7, e50887. https://doi.org/10.1371/journal.pone.0050887
  27. Rock FL, Hardiman G, Timans JC, et al (1998). A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A, 95, 588-93. https://doi.org/10.1073/pnas.95.2.588
  28. Roses RE, Xu M, Koski GK, Czerniecki BJ (2008). Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene, 27, 200-7. https://doi.org/10.1038/sj.onc.1210909
  29. Slattery ML, Herrick JS, Bondurant KL, Wolff RK (2012). Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer, 130, 2974-80. https://doi.org/10.1002/ijc.26314
  30. Takeuchi O, Hoshino K, Kawai T, et al (1999). Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity, 11, 443-51. https://doi.org/10.1016/S1074-7613(00)80119-3
  31. Takeuchi O, Kawai T, Sanjo H, et al (1999). TLR6: A novel member of an expanding toll-like receptor family. Gene, 231, 59-65. https://doi.org/10.1016/S0378-1119(99)00098-0
  32. Theodoropoulos GE, Saridakis V, Karantanos T, et al (2012). Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast, 21, 534-8. https://doi.org/10.1016/j.breast.2012.04.001
  33. Thomas KH, Meyn P, Suttorp N (2006). Single nucleotide polymorphism in 5'-flanking region reduces transcription of surfactant protein B gene in H441 cells. Am J Physiol Lung Cell Mol Physiol, 291, L386-90. https://doi.org/10.1152/ajplung.00193.2005
  34. Tian T, Jin S, Dong J, Li G (2012). Lack of association between Toll-like receptor 4 gene Asp299Gly and Thr399Ile polymorphisms and tuberculosis susceptibility: A metaanalysis. Infect Genet Evol, 14C, 156-60.
  35. Tierney MJ, Medcalf RL (2001). Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAs. J Biol Chem, 276, 13675-84.
  36. Tsan MF (2006). Toll-like receptors, inflammation and cancer. Semin Cancer Biol, 16, 32-7. https://doi.org/10.1016/j.semcancer.2005.07.004
  37. Wang RF, Miyahara Y, Wang HY (2008). Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene, 27, 181-9. https://doi.org/10.1038/sj.onc.1210906
  38. Wang X, Li J, Xie W, et al (2013). Toll-like receptor 2 gene polymorphisms and cancer susceptibility: a meta-analysis. Neoplasma, 60, 459-67. https://doi.org/10.4149/neo_2013_060
  39. Yang ZH, Dai Q, Gu YJ, et al (2012). Cytokine and chemokine modification by Toll-like receptor polymorphisms is associated with nasopharyngeal carcinoma. Cancer Sci, 103, 653-8. https://doi.org/10.1111/j.1349-7006.2012.02210.x
  40. Zeng HM, Pan KF, Zhang Y, et al (2011). [The correlation between polymorphisms of Toll-like receptor 2 and Toll-like receptor 9 and susceptibility to gastric cancer]. Zhonghua Yu Fang Yi Xue Za Zhi, 45, 588-92.
  41. Zhou XX, Jia WH, Shen GP, et al (2006). Sequence variants in toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol Biomarkers Prev, 15, 862-6. https://doi.org/10.1158/1055-9965.EPI-05-0874

Cited by

  1. TLR9 Expression in Uterine Cervical Lesions of Uyghur Women Correlate with Cervical Cancer Progression and Selective Silencing of Human Papillomavirus 16 E6 and E7 Oncoproteins in Vitro vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5867